

# Hind Rafei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135866/publications.pdf>

Version: 2024-02-01

52  
papers

757  
citations

759233

12  
h-index

552781

26  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1401  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Graft Versus Host Disease: A Comprehensive Review. <i>Anticancer Research</i> , 2017, 37, 1547-1555.	1.1	159
2	Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1250-1259.	2.0	71
3	Immune-based Therapies for Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 377-388.	1.1	66
4	Recent advances in the treatment of acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2606-2621.	1.3	65
5	Chimeric antigen receptor (CAR) natural killer (NK) cell therapy: leveraging the power of innate immunity. <i>British Journal of Haematology</i> , 2021, 193, 216-230.	2.5	61
6	Hereditary myeloid malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 163-176.	1.7	35
7	Microbiome-intestine cross talk during acute graft-versus-host disease. <i>Blood</i> , 2020, 136, 401-409.	1.4	34
8	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	1.6	32
9	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	5.2	29
10	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 207-223.	2.5	20
11	Targeting advanced urothelial carcinoma-developing strategies. <i>Current Opinion in Oncology</i> , 2019, 31, 207-215.	2.4	14
12	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
13	A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. <i>Biomedicines</i> , 2017, 5, 60.	3.2	12
14	Post-diagnosis aspirin use and survival in veterans with head and neck cancer. <i>Head and Neck</i> , 2019, 41, 1220-1226.	2.0	12
15	DA-EPOCH-R for post-transplant lymphoproliferative disorders. <i>European Journal of Haematology</i> , 2017, 99, 283-285.	2.2	11
16	Disseminated intravascular coagulation-like reaction following rituximab infusion. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218443.	0.5	11
17	Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH. <i>Blood</i> , 2016, 128, 5396-5396.	1.4	11
18	Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 10.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. <i>Leukemia and Lymphoma</i> , 2019, 60, 3292-3295.	1.3	10
20	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 107-114.	1.2	9
21	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 1-12.	0.9	7
22	Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 317-329.	1.3	7
23	Editorial: Cellular Therapies in Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2788.	4.8	7
24	Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 803-807.	1.7	6
25	Post-Transfusion Purpura: A Case Report of an Underdiagnosed Phenomenon. <i>Cureus</i> , 2017, 9, e1207.	0.5	6
26	A rare breed: Wild-type braf and ighv expression in a 29 year old lady with classical hairy cell leukemia. <i>Leukemia Research Reports</i> , 2017, 7, 20-22.	0.4	4
27	Monozygotic twins with GATA2 deficiency: same haploidentical-related donor, different severity of GvHD. <i>Bone Marrow Transplantation</i> , 2017, 52, 1580-1582.	2.4	4
28	Current Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 107-147.	1.6	3
29	Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel approach.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6004-6004.	1.6	3
30	Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. <i>Blood</i> , 2019, 134, 735-735.	1.4	2
31	Platelet Count Increase Seen with Ledipasvir-Sofosbuvir Combination Treatment of Chronic Hepatitis C in Patients with Thrombocytopenia. <i>Blood</i> , 2016, 128, 5967-5967.	1.4	2
32	Aspirin use and survival in head and neck squamous cell cancer (HNC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6042-6042.	1.6	2
33	Phase II study: Induction chemotherapy & transoral surgery as definitive tx for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)â€”A novel approach.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6078-6078.	1.6	2
34	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	1.6	2
35	Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review. <i>Case Reports in Hematology</i> , 2017, 2017, 1-4.	0.4	1
36	Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7008-7008.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2019, 37, 7049-7049.	1.6	1
38	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood, 2020, 136, 23-25.	1.4	1
39	Bendamustine appears to be a safe and effective alternative to carmustine when combined with etoposide, cytarabine and melphalan as conditioning regimen for autologous HCT for lymphomas: results of a systematic review/meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S361.	0.4	0
40	Prognostic Impact of Full Hematologic Recovery and Achievement of Measurable Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) After First Salvage Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S218-S219.	0.4	0
41	The Future of Cellular Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S102-S105.	0.4	0
42	AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S201-S202.	0.4	0
43	Perspective of Lebanese Oncologists on the Symptom Burden among Adult Cancer Patients. Journal Medical Libanais, 2016, 64, 200-204.	0.0	0
44	Prevalence of Inherited and Acquired Thrombophilia in Females Post Multiple Assisted Reproductive Technology (ART) Attempts. Blood, 2016, 128, 3535-3535.	1.4	0
45	Low Prevalence of CD30 Expression in Diffuse Large B-Cell Lymphoma Patients with MYC Expression. Blood, 2016, 128, 3561-3561.	1.4	0
46	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. Blood, 2019, 134, 3596-3596.	1.4	0
47	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. Blood, 2020, 136, 40-42.	1.4	0
48	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. Blood, 2020, 136, 2-4.	1.4	0
49	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. Blood, 2020, 136, 39-41.	1.4	0
50	Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood, 2020, 136, 1-1.	1.4	0
51	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood, 2020, 136, 45-47.	1.4	0
52	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood, 2020, 136, 36-38.	1.4	0